china, india and personalised medicine · is ascribed to the financial constraints that are common...
Post on 24-Aug-2020
1 Views
Preview:
TRANSCRIPT
China, India and personalised medicine
Stuart Hogarth, Department of Social Science, Health and Medicine,
King’s College London
Overview
• Governing biomedical innovation
• The evolving personalised medicine landscape
• Governance challenges: India and China
– Targeted therapeutics and companion diagnostics
– Early detection/screening
What’s in a name?
• Personalised medicine
• Stratified medicine
• Precision medicine
• P4 medicine
What’s in a name
0
200
400
600
800
1000
1200
1400
1600
1800
2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997
Pu
blic
atio
ns
Changing terminology
pharmacogenomics
pharmacogenetics
personalis/zed medicine
stratified medicine
precision medicine
What’s in a name?
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
pharmacogenomics pharmacogenetics personalis/zed medicine stratified medicine precision medicine
ne
ws
ite
ms
News coverage Aug 2013- Aug 2015
Which ‘omics?
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000
Pu
blic
atio
ns
Growth in 'omics research 2000-2014
genomics
proteomics
metabolomics
microbiome
Genomic determinism
• Cheaper, faster sequencing critical goal
• Will inevitably lead to a revolution in medicine
• One model of implementation – universal incorporation of genome sequence in medical record
Technological trajectories
• High throughput
– Next generation sequencing
– Microarrays
• Automation
– sample to results
– deskilling
– cost reduction
– POC
Point of Care DNA Dx
Targeted Rx + companion Dx
1998 - FDA approval of Herceptin and HercepTest for breast cancer patients with HER2+ tumors
FDA approved Rx with companion Dx
Non-small cell lung cancer Iressa (gefitinib) Xalkori (crizotinib) Gilotrif (afatinib) Tarceva (erlotinib) Colorectal cancer Erbitux (cetuximab) Vectibix (panitumumab) Ovarian cancer Lynparza (olaparib) Gastrointestinal stromal
tumors Gleevec/Glivec (imatinib
mesylate)
Cystic Fibrosis Kalydeco (ivacaftor) Thalassemia Exjade (deferasirox)
Breast cancer Herceptin (trastuzumab) Perjeta (pertuzumab); Kadcyla (ado-trastuzumab emtansine) Melanoma Mekinist (tramatenib); Tafinlar (dabrafenib) Zelboraf
Access issues
... an estimated 441 patients were eligible to receive HER2-targeted therapy in the year 2008 in our institution. However, only 8.61% of these patients were able to receive such treatment and nearly half (4.54%) of the HER2-targeted therapy was through patient participation in clinical trials. The low usage of a highly effective treatment is ascribed to the financial constraints that are common in our patients and a healthcare delivery model wherein the majority of patients have no access to any form of health insurance.
Ghosh et al Ind Jnl Cancer, 2011
GLOBOCAN estimates of worldwide burden of cervical cancer 2008
International Journal of Cancer Volume 127, Issue 12, pages 2893-2917, 17 JUN 2010 DOI: 10.1002/ijc.25516 http://onlinelibrary.wiley.com/doi/10.1002/ijc.25516/full#fig12
Australia, 1
Belgium, 1 Canada, 2
China, 5
Denmark, 1
France, 1
Germany, 7
Hong Kong, 2
Hungary, 1
Italy, 5
Japan, 3
Netherlands, 3
Norway, 1 Russia, 2
South Korea, 13
Spain, 5
Switzerland, 2
Taiwan, 2
UK, 1
USA, 12
careHPV
• 2003 - Digene partner with PATH and Bill & Melinda Gates Foundation on test for LMIC
• 2012 – SFDA approve careHPV test for use in China – Stable at extreme temperatures
– Simple robust procedure
– Works in low-resource setting
– Low cost
The broader medtech market
top related